Why IMU is a multi multi bagger, page-19796

Kluck, RenovoRx has just announced that they are presenting at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, March 23-28 in Salt Lake City.

This should give us a pretty good look at how effective TAMP is likely to be and, thus how beneficial TAMP will be for delivering CF33 to hard reach solid tumors.

RenovoRX:

"We are pleased to present research supporting our TAMP therapy platform at the upcoming SIR 2024 conference, the largest professional gathering of interventional radiologists in North America,” said Shaun Bagai, CEO of RenovoRx. “This research adds to the continued progress of our pivotal Phase III TIGeR-PaC study in LAPC. We remain steadfast in our commitment to deliver transformative therapies to potentially extend and improve the quality of life of cancer patients.”

_{Presentation Details:}

_{Title: Mesenteric Venous Thrombosis as aPredictor of Target Artery Thrombosis and Tran-Arterial Micro PerfusionTreatment Completion Among Patients with Locally Advanced PancreaticCancer}

_{Authors: Michel Accad, MD, et al.}Abstract ID: 1632169

Website: 2024 SIR Annual Scientific Meeting (sirmeeting.org)

GLTAH